Clinical Trial Update: A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating filgotinib 200 mg in Korean patients with moderate-to-severe ulcerative colitis is currently recruiting in routine clinical practice.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Filgotinib (filgotinib)

Snippet

Sponsor: Eisai Korea Inc. | Conditions: Ulcerative Colitis | Phase 4 | Status: RECRUITING